Pentostatin in steroid-refractory acute graft-versus-host disease - Wikidata - wikimedia - TriplyDB

Pentostatin in steroid-refractory acute graft-versus-host disease

Pentostatin in steroid-refractory acute graft-versus-host disease

http://www.wikidata.org/entity/Q28245825

about

Secondary treatment of acute graft-versus-host disease: a critical review Pentostatin in chronic lymphocytic leukemia Safety and efficacy of low-dose methotrexate for pediatric patients with steroid-refractory acute graft-versus-host disease after hematopoietic stem cell transplantation.Current and future approaches for control of graft-versus-host disease.Pathogenesis and management of graft-versus-host disease.Prophylaxis of graft-versus-host disease in unrelated donor transplantation with pentostatin, tacrolimus, and mini-methotrexate: a phase I/II controlled, adaptively randomized study The pentostatin plus cyclophosphamide nonmyeloablative regimen induces durable host T cell functional deficits and prevents murine marrow allograft rejection.Pentostatin plus cyclophosphamide safely and effectively prevents immunotoxin immunogenicity in murine hosts.Management of acute graft-versus-host disease in children.Efficacy of Mesenchymal Stem Cell Therapy for Steroid-Refractory Acute Graft-Versus-Host Disease following Allogeneic Hematopoietic Stem Cell Transplantation: A Systematic Review and Meta-Analysis.Acute graft versus host disease.Immunotherapy following hematopoietic stem cell transplantation: potential for synergistic effects Tocilizumab for steroid refractory acute graft-versus-host disease Lymphocyte phenotype during therapy for acute graft-versus-host disease: a brief report from BMT-CTN 0302.Concise review: acute graft-versus-host disease: immunobiology, prevention, and treatment.Treatment options in steroid-refractory acute graft-versus-host disease following hematopoietic stem cell transplantation.Tocilizumab for the treatment of steroid refractory graft-versus-host disease.Standard pentostatin dose reductions in renal insufficiency are not adequate: selected patients with steroid-refractory acute graft-versus-host disease.Etanercept, mycophenolate, denileukin, or pentostatin plus corticosteroids for acute graft-versus-host disease: a randomized phase 2 trial from the Blood and Marrow Transplant Clinical Trials Network Treatment and management of graft-versus-host disease: improving response and survival.Acute graft-versus-host disease: are we close to bringing the bench to the bedside?Therapy with mycophenolate mofetil for refractory acute and chronic GVHD.Emerging drugs for acute graft-versus-host disease.Mesenchymal stem cells targeting the GVHD.Acute graft-versus-host disease: new treatment strategies.The use of monoclonal antibodies for the treatment of graft-versus-host disease following allogeneic stem cell transplantation.State-of-the-art acute and chronic GVHD treatment.Mesenchymal Stromal Cells for Treatment of Acute Steroid-Refractory Graft Versus Host Disease: Clinical Responses and Long-Term Outcome.Mycophenolate pharmacokinetics and association with response to acute graft-versus-host disease treatment from the Blood and Marrow Transplant Clinical Trials Network Sirolimus for treatment of steroid-refractory acute graft-versus-host disease.Mycophenolate mofetil for the management of steroid-refractory acute graft vs host disease.Pentostatin for treatment of steroid-refractory acute GVHD: a retrospective single-center analysis.Limited benefit of pentostatin salvage therapy for steroid-refractory grade III-IV acute graft-versus-host disease.Extracorporeal photopheresis for the treatment of acute and chronic graft-versus-host disease in adults and children: best practice recommendations from an Italian Society of Hemapheresis and Cell Manipulation (SIdEM) and Italian Group for Bone Marr Low-dose MTX for the treatment of acute and chronic graft-versus-host disease in children.What is the outcome in patients with acute leukaemia who survive severe acute graft-versus-host disease?Successful treatment with placenta-derived decidual stromal cells in a pediatric patient with life-threatening acute gastrointestinal graft-versus-host disease.Pentostatin therapy for steroid-refractory acute graft versus host disease: identifying those who may benefit.New and emerging therapies for acute and chronic graft versus host disease.Reversal of Low Donor Chimerism after Hematopoietic Cell Transplantation Using Pentostatin and Donor Lymphocyte Infusion: A Prospective Phase II Multicenter Trial.

P2860

Q26823275-7E20F409-4861-4505-9BFD-F2B86CBC40B1 Q28291531-BE87781D-E6ED-451D-AEE7-7579A68CC731 Q33411063-16730F3F-9191-4EB6-9B55-52C0404631CF Q33642625-64974A42-17D8-4CCF-B78E-193650929B36 Q34077479-66651D58-6F3A-495A-9B83-5B628E94C18C Q34666851-51252F0A-13DA-444B-941C-8D371E02A5C4 Q34700443-C09CE070-0AA9-4F1A-927C-19AF3CF56019 Q35023967-F9F88AD7-2D9F-4E5F-9E9B-12EC0B3A1EF4 Q35583009-53615EB1-9DFA-4B8D-AAA2-A9C41554D138 Q35760517-8646C55C-EB9B-4B01-B876-4CB0D7C663E1 Q36059671-D4687C2F-C159-4DF9-846F-E06567DF85EA Q36380188-CD2479DE-5069-4BB5-87A7-C13B7CB9ADA9 Q36422339-D03452CB-1BE2-481A-88DC-A19DEE5D1F87 Q36841805-45D676F7-AC75-4F95-A231-4D3E50A79797 Q36861714-06599430-A58C-4D82-8F4F-3A40A71DE80F Q36904078-3DC6C790-D7C0-48FC-A18E-0DCAE697C20B Q37026278-02CAA216-8DCC-4935-94CD-3A99076D3DC7 Q37039069-F02A5860-1E7B-47EB-BD67-20C068EA752C Q37268948-22D5D99A-7B94-480A-826A-342EF83498C8 Q37371836-436F5E55-CEFB-47EF-84DA-9052FDA83F70 Q37402799-C1401268-B00A-4044-B4D6-D0184F4C53FC Q37468247-268CA0F9-3247-4CFB-8664-CFFC6485C0EE Q37515433-8E5F680F-F1BE-45DB-948C-78BB36E2933E Q37566315-3DF96E84-C039-46AA-81D9-777BDDA914D2 Q37610714-400A94F3-AFA1-4263-9413-FB0BA7E79216 Q37851519-6B0E0EAA-F074-4122-8AD2-9B091B58892C Q38416376-ACF1CC8D-6666-4866-A49F-709EFB765FD6 Q41290373-23B538BC-5EB5-4612-81CD-E9CA4E7E0037 Q42149848-3CBD8C9E-5252-4E90-AF19-38E1FC86FC33 Q43228479-811078B2-ED42-4418-B85D-F98EF816A900 Q43273885-2979B009-FD3B-434C-AB81-B79F32C7A5EC Q44005585-2384B629-F359-4236-98FF-C37512AB7FB1 Q44847537-9A797F79-0310-40AA-83DD-6BD1A924B863 Q46584471-6A475532-6385-4D18-B815-2CB3BB22BCF0 Q46890990-14CB51E5-BFC3-43A4-AC29-0C1458C7E9BC Q48191465-D2BF71C6-C428-4BF1-A10F-393C0EF01ED3 Q48281486-335D16D1-C473-4F2F-A585-54A11E5FAD5F Q48362201-5B35DB79-6106-4212-A822-F5F44D0ED671 Q49238507-CF50EA49-5C9E-492F-8AF9-F17CB93247D1 Q50069823-A6EE1628-A37C-48C4-A2D3-7E1BE3714D0D

P2860

Pentostatin in steroid-refractory acute graft-versus-host disease

http://www.wikidata.org/entity/Q28245825

description

2005 nî lūn-bûn

@nan

2005 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2005 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2005年の論文

@ja

2005年論文

@yue

2005年論文

@zh-hant

2005年論文

@zh-hk

2005年論文

@zh-mo

2005年論文

@zh-tw

2005年论文

@wuu

name

Pentostatin in steroid-refractory acute graft-versus-host disease

@ast

Pentostatin in steroid-refractory acute graft-versus-host disease

@en

Pentostatin in steroid-refractory acute graft-versus-host disease

@nl

type

label

Pentostatin in steroid-refractory acute graft-versus-host disease

@ast

Pentostatin in steroid-refractory acute graft-versus-host disease

@en

Pentostatin in steroid-refractory acute graft-versus-host disease

@nl

prefLabel

Pentostatin in steroid-refractory acute graft-versus-host disease

@ast

Pentostatin in steroid-refractory acute graft-versus-host disease

@en

Pentostatin in steroid-refractory acute graft-versus-host disease

@nl

P1433

Q28245825-1BD74F83-CBF2-457B-B88A-6BAF786137F9

P1476

Q28245825-80F4BCEB-FC60-444D-A71F-6D5742645C63

P2093

Q28245825-001A365A-9775-4599-A89E-52765B1A0241

Q28245825-081B149F-259F-4D05-B108-F7F3AECF2D1E

Q28245825-095840C0-A6C2-4D7C-B45A-8AD9B381B9CD

Q28245825-21DCC286-362C-4E3C-B105-FD292CBE98B3

Q28245825-4F555E99-CF81-4869-8570-C6FC46F28DBF

Q28245825-54AF2EB7-CAFA-4CB4-9F1B-8C3B3A0E12A4

Q28245825-5D2896F2-D0AB-48EA-897E-556B28D4B5B7

Q28245825-705C6EDF-8BA2-473F-B6D8-508713CD42BF

Q28245825-B5E5DB31-1068-41FA-8C5F-7EA9F26640CF

Q28245825-F321993B-F25F-48A9-9C08-FD6DE4BE1D2B

P304

Q28245825-C439C137-4A37-4A8B-90EA-5367EA95EA2E

P31

Q28245825-73568CE1-C630-4DBD-8215-D8DEEC904B76

P356

Q28245825-AFB8ECE3-0C48-446A-B2A7-DD48C8BA8604

P407

Q28245825-0CBB9A02-6F16-4F73-8F3A-36AF64E91E7C

P433

Q28245825-4D33BC8D-33D2-46B7-9164-3AC67A3839D7

P478

Q28245825-5DF4130F-B448-4B10-B1E7-0827142B3CCE

P50

Q28245825-764385D2-17DD-4A30-8722-75AFFD983B76

P577

Q28245825-61CA7CF2-CFB0-4A13-B0E5-6214F5527978

P5875

Q28245825-C09459D5-0B37-4454-9B9F-E82430288B97

P698

Q28245825-8D8C2CDC-4A98-4F6D-B98D-270532767414

P356

JCO.2005.06.130

P1433

Journal of Clinical Oncology

P1476

Pentostatin in steroid-refractory acute graft-versus-host disease

@en

P2093

Adam Ogden

http://www.w3.org/2001/XMLSchema#string

David A Jacobsohn

http://www.w3.org/2001/XMLSchema#string

David M Lucas

http://www.w3.org/2001/XMLSchema#string

Georgia B Vogelsang

http://www.w3.org/2001/XMLSchema#string

Javier Bolaños-Meade

http://www.w3.org/2001/XMLSchema#string

Jeffrey Margolis

http://www.w3.org/2001/XMLSchema#string

M Guillaume Wientjes

http://www.w3.org/2001/XMLSchema#string

Michael R Grever

http://www.w3.org/2001/XMLSchema#string

Michele Phelps

http://www.w3.org/2001/XMLSchema#string

Viki Anders

http://www.w3.org/2001/XMLSchema#string

P304

2661-8

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1200/JCO.2005.06.130

http://www.w3.org/2001/XMLSchema#string

P407

P433

12

http://www.w3.org/2001/XMLSchema#string

P478

23

http://www.w3.org/2001/XMLSchema#string

P50

P577

2005-04-20T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

7899229

http://www.w3.org/2001/XMLSchema#string

P698

15837980

http://www.w3.org/2001/XMLSchema#string